Monday 2 November 2026 Export TWST’s income statement to Excel — free account

Twist Bioscience Corporation

Twist Bioscience Corporation’s revenue for fiscal 2025 (year ended September 2025) was $376.6 million, up 20.3% from fiscal 2024.

Revenue: +23.2%
EPS: −264.7%
Free cash flow: −7.23%
Total debt: 0.00%

Quarter to June 2026, against a year earlier

129.86 22.92 −15.00%

Follow TWST

Alert me

Market cap: $10.1B
P/E: 0.0×
Fwd P/E: −91.4×
Dividend yield: —
F-score: 4/9
Altman Z: 3.44
Beneish M: −2.30
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Filings

Twist Bioscience Corporation (TWST) revenue by segment, product and region

Revenue by product or service $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017
NGS applications	208 55.26%	169 54.04%	124 50.47%	99 48.79%	73 54.91%	44 48.85%	21 38.69%	3 10.49%	0 0.67%
Synthetic genes	114 30.17%	93 29.61%	74 30.00%	62 30.22%	39 29.44%	35 39.06%	27 49.12%	18 70.74%	8 75.43%
DNA synthesis and protein solutions	23 6.23%	20 6.50%	23 9.45%	24 11.87%	7 5.28%	2 2.64%	—	—	—
Oligo pools	20 5.37%	17 5.40%	14 5.91%	12 6.10%	8 6.07%	5 5.04%	5 8.45%	3 11.81%	2 19.10%
DNA libraries	11 2.97%	14 4.45%	10 4.16%	6 3.02%	6 4.29%	4 4.40%	2 3.74%	2 6.97%	1 4.80%
Revenue	377	313	245	204	132	90	54	25	11

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2020	FY2019	FY2018	FY2017
Reportable Segment	377 100.00%	313 100.00%	245 100.00%	—	—	—	—
Health Care	—	—	—	40 44.44%	17 32.04%	4 16.57%	1 11.39%
Industrial Chemicals	—	—	—	29 32.25%	22 40.32%	15 58.65%	7 62.25%
Academic Research	—	—	—	20 21.80%	14 25.44%	6 22.86%	3 25.16%
Food And Agriculture	—	—	—	1 1.52%	1 2.20%	0 1.93%	—
Agricultural	—	—	—	—	—	—	0 1.21%
Revenue	377	313	245	90	54	25	11

Operating income by segment $m, and margin

	FY2025	FY2024	FY2023	FY2020	FY2019	FY2018	FY2017
Reportable Segment	‡	‡	‡	‡	‡	‡	‡
Corporate and other	‡	‡	‡	‡	‡	‡	‡
Operating income	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017
Americas	226 59.90%	194 61.95%	151 61.71%	122 60.16%	78 58.87%	59 65.66%	37 67.91%	0 0.81%	—
EMEA	124 32.99%	93 29.58%	71 29.13%	62 30.50%	44 33.34%	26 28.66%	15 27.01%	7 25.79%	2 18.79%
APAC	27 7.10%	27 8.47%	22 9.16%	19 9.34%	10 7.78%	5 5.68%	3 5.08%	1 3.94%	0 2.54%
United States	—	—	—	—	—	—	—	18 69.46%	8 76.56%
North America	—	—	—	—	—	—	—	—	0 2.11%
Revenue	377	313	245	204	132	90	54	25	11

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
Customers shipped to	Q3 FY2026	2.7K	2.5K	+6.68%
Genes shipped	Q3 FY2026	369.0K	237.0K	+55.70%
Remaining performance obligations	Q3 FY2026	$21.9M	$13.4M	+63.43%

	Q3 FY2026	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024	Q4 FY2023	Q3 FY2023	Q2 FY2023	Q4 FY2022
Customers shipped to	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Genes shipped	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Remaining performance obligations	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.